Experimental drug aims to clear lungs in rare genetic disease
NCT ID NCT06633757
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This early-stage study tested an experimental drug called RCT1100 in 14 adults with primary ciliary dyskinesia (PCD) caused by a specific genetic change in the DNAI1 gene. The goal was to see if the drug could improve how the lungs clear mucus and to check for safety. The results will help plan future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CILIARY DYSKINESIA (PCD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Copenhagen University Hospital - Rigshospitalet
Copenhagen, 2100, Denmark
-
Münster University Hospital, Albert-Schweitzer-Campus 1
Münster, North Rhine-Westphalia, 48149, Germany
-
UNC
Chapel Hill, North Carolina, 27514, United States
Conditions
Explore the condition pages connected to this study.